Preclinical in vivo studies form the cornerstone of drug development and translation,
bridging in vitro experiments with first-in-human trials. However, despite the utility of animal …

Significant scientific advances in biomedical research have expanded our knowledge of the
molecular basis of carcinogenesis, mechanisms of cancer growth, and the importance of the …

Every patient and every disease is different. Each patient therefore requires a personalized
treatment approach. For technical reasons, a personalized approach is feasible for treatment …

Translational model‐based approaches have played a role in increasing success in the
development of novel anticancer treatments. However, despite this, significant translational …

Antibody‐drug conjugates (ADCs) have gained traction in the oncology space in the past
few decades, with significant progress being made in recent years. Although the use of …

Translational models directly relating drug response specific processes that can be
observed in vitro to their in vivo role in cancer patients constitute a crucial part of the …

Experimental animal tumor models have been broadly used to evaluate anticancer drugs in
the preclinical setting. They have also been widely applied for drug target discovery and …

Despite advances in biomedical research that have deepened our understanding of cancer
hallmarks, resulting in the discovery and development of targeted therapies, the success …

Background and purpose Predicting the efficacy of anticancer therapy is the holy grail of
drug development and treatment selection in the clinic. To achieve this goal, scientists …

Recent progress in understanding the molecular basis of cellular processes, identification of
promising therapeutic targets and evolution of the regulatory landscape makes this an …